Gastrointestinal Therapeutics Market Research Report 2024 – 2032
Increase in prevalence of gastrointestinal diseases, increase in the geriatric population suffering from gastrointestinal disorders, surge in demand for effective treatment options, and rise in prevalence of ulcerative colitis and Crohn’s disease are the factors expected to drive the gastrointestinal therapeutics market.
According to the report, the global gastrointestinal therapeutics industry generated $39.5 billion in 2022, and is anticipated to generate $64.5 billion by 2032, witnessing a CAGR of 5.0% from 2023 to 2032.
Gastrointestinal therapeutics is a specialized medical discipline dedicated to the diagnosis and management of disorders that affect the gastrointestinal tract. Within this medical field, the primary emphasis is on addressing conditions that impact various organs within the gastrointestinal system, including the stomach, small intestine, large intestine, and rectum. Gastrointestinal therapeutics encompass a broad spectrum of interventions, including the use of medications to alleviate symptoms, enhance the overall functioning of the gastrointestinal system, and improve the quality of life for individuals dealing with these ailments.
Request Sample of the Report:
https://www.alliedmarketresearch.com/request-sample/3535
Key Takeaways:
- The biologics segment to maintain its leadership status throughout the forecast period
- The inflammatory bowel disease segment to maintain its leadership status throughout the forecast period
- The drug stores and retail pharmacies segment to maintain its lead position during the forecast period
- North America to maintain its dominance by 2032 .
Recession Impact :
- During a recession, individuals and governments might tighten their budgets, leading to reduced healthcare spending. This could affect patient ability to access and afford gastrointestinal medications and treatments, potentially leading to decreased demand for these therapeutics. In addition, economic uncertainty during a recession might cause individuals to delay or avoid non-essential medical visits, including routine check-ups for gastrointestinal issues.
- However, the rise in research and development activities for gastrointestinal therapeutics and increase in number of pipeline products for gastrointestinal diseases is experiencing a moderate positive impact from the global recession.
The growth of the gastrointestinal therapeutics market can be influenced by various factors. Here are some key ones:
- Prevalence of Gastrointestinal Disorders: The incidence and prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and others drive the demand for gastrointestinal therapeutics.
- Technological Advancements: Innovations in drug delivery systems, such as targeted drug delivery and sustained-release formulations, can enhance the efficacy and safety of gastrointestinal therapeutics, thereby driving market growth.
- Rising Geriatric Population: Aging populations are more susceptible to gastrointestinal disorders, leading to an increased demand for gastrointestinal therapeutics.
- Changing Lifestyles and Dietary Habits: Factors such as sedentary lifestyles, unhealthy dietary habits, and stress contribute to the prevalence of gastrointestinal disorders, thereby driving the demand for therapeutics.
- Increasing Awareness and Diagnosis: Growing awareness about gastrointestinal disorders and advancements in diagnostic techniques lead to early detection and treatment, thereby boosting the demand for gastrointestinal therapeutics.
Market Segmentation:
Type of Disorder:
- Gastroesophageal Reflux Disease (GERD)
- Inflammatory Bowel Disease (IBD) (including Crohn’s disease and ulcerative colitis)
- Irritable Bowel Syndrome (IBS)
- Peptic Ulcer Disease
- Gastrointestinal Cancers
- Others (such as gastroparesis, celiac disease, and diverticular disease)
Type of Drug:
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Antagonists
- Antidiarrheals
- Antiemetics
- Immunomodulators
- Biologics (such as TNF-alpha inhibitors)
- Antacids
- Others (including antibiotics, laxatives, and steroids)
Route of Administration:
- Oral
- Parenteral (intravenous or subcutaneous)
- Rectal
- Topical (such as creams or ointments for certain gastrointestinal disorders)
- Others (such as nasogastric or gastrostomy tube administration for specific cases)
Geography:
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
- Latin America (Brazil, Colombia, Argentina, Rest of Latin America)
- Middle East and Africa (Gcc, South Africa, North Africa, Rest Of Mea)
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Others (including specialty clinics and institutional sales)
End User:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Homecare Settings
https://www.alliedmarketresearch.com/checkout-final/gastrointestinal-therapeutics-market
Regional Analysis:
North America held the largest market share in terms of revenue in 2022, accounting for more than two-fifths of the global gastrointestinal therapeutics market revenue and is likely to dominate the market during the forecast period. Easy availability of drugs for treatment, well-developed healthcare infrastructure, and rise in prevalence of gastrointestinal diseases promoted the growth of the gastrointestinal therapeutics market in North America.
Asia-Pacific region is expected to witness the fastest CAGR of 6.4% from 2023 to 2032. High prevalence of geriatric population with increase in need of diagnostic procedures, surge in prevalence of gastrointestinal diseases, rise in research and development activities in fields such as pharmaceuticals, and life sciences and surge in healthcare expenditure in the Asia-Pacific region, is expected to drive the growth of the gastrointestinal therapeutics market.
Connect to our Analyst:
https://www.alliedmarketresearch.com/connect-to-analyst/3535
Competitive Landscape
The key players in the global gastrointestinal therapeutics market are:
- AbbVie Inc.
- Astrazeneca plc
- Pfizer Inc.
- Bayer AG
- Bausch Health Companies Inc.
- Takeda Pharmaceutical Company Limited
- Cosmo Pharmaceuticals
- Organon Group of Companies
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Limited
Buy this Premium Research Report:
https://www.alliedmarketresearch.com/purchase-enquiry/3535
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact Data:
David Correa
1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA.
Toll Free: +1-800-792-5285| Int’l: +1-503-894-6022
UK: +44-845-528-1300| Hong Kong: +852-301-84916
Web: https://www.alliedmarketresearch.com
Explore More Reports:
The global constipation treatment market is projected to reach $10.1 billion by 2032
The global gastrointestinal therapeutics market is projected to reach $64.5 billion by 2032
The global cath lab services market is projected to reach $78.2 billion by 2032
The global advanced wound care market size is projected to reach $17.8 billion by 2032